Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 1.00 |
| ▸ | EPHA2 | P29317 | 4/20 | 1.00 |
| ▸ | VDR | P11473 | 2/20 | 1.00 |
| ▸ | CASP7 | P55210 | 3/20 | 0.80 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.80 |
| ▸ | TP53 | P04637 | 2/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.80 |
| ▸ | BLM | P54132 | 2/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.80 |
| ▸ | USP2 | O75604 | 2/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.80 |
| ▸ | MDM4 | O15151 | 1/20 | 0.80 |
| ▸ | MAPT | P10636 | 1/20 | 0.80 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.80 |
| ▸ | TSHR | P16473 | 1/20 | 0.80 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.80 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.80 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithoglycocholate SCHEMBL5062943 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2VDRCASP7NR1H4 | |
| Lithoglycocholate SCHEMBL17309134 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2VDRCASP7NR1H4 | |
| Lithoglycocholate SCHEMBL5062937 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2VDRCASP7NR1H4 | |
| Lithoglycocholate SCHEMBL27044630 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2VDRCASP7NR1H4 | |
| Lithoglycocholate SCHEMBL13851599 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2VDRCASP7NR1H4 | |
| Lithoglycocholate SCHEMBL24001379 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2VDRCASP7NR1H4 | |
| Lithoglycocholate SCHEMBL5062940 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2VDRCASP7NR1H4 | |
| Lithoglycocholate SCHEMBL736797 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2VDRCASP7NR1H4 | |
| Lithoglycocholate SCHEMBL25710569 | 1.00 | GPBAR1 (1.00) | GPBAR1EPHA2VDRCASP7NR1H4 | |
| Lithoglycocholate SCHEMBL232623 | 0.96 | GPBAR1 (0.93) | GPBAR1EPHA2VDRCASP7NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 712 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3869192-B1 | METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE | HUMAN METABOLOMICS INST INC (CN) | 2026-05-13 | — | — | EP | claimed |
| CN-122017068-A | Bile acid high-flux detection method based on ultra-high performance liquid chromatography tandem mass spectrometry and application thereof | 青岛百谱生物科技有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-12569502-B2 | Use of bile acids and derivatives thereof in preparation of GPR39 agonist | PEKING UNIVERSITY (CN) | 2026-03-10 | — | — | US | claimed |
| EP-4262876-B1 | COVALENTLY MODIFIED ANTIGENS FOR IMPROVED IMMUNE RESPONSE AND/OR STABILITY | DEFENCE THERAPEUTICS INC (CA) | 2026-02-25 | — | — | EP | claimed |
| EP-4638478-A1 | COVALENTLY-MODIFIED STEROID ACID-PEPTIDES HAVING ENHANCED STABILITY AND/OR BIOLOGICAL ACTIVITY | Defence Therapeutics Inc. (CA) | 2025-10-29 | — | — | EP | claimed |
| US-20250273338-A1 | BIOMARKERS FOR DETECTING COLORECTAL CANCER OR COLORECTAL ADENOMA AND METHODS THEREOF | Precogify Pharmaceutical China Co., Ltd. (CN) | 2025-08-28 | — | — | US | claimed |
| US-20250258146-A1 | QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP | HUMAN METABOLOMICS INSTITUTE INC. (CN) | 2025-08-14 | — | — | US | claimed |
| CN-120064484-A | LC-MS/MS method for detecting bile acid in biological sample | 武汉迈维代谢生物科技股份有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-120009427-A | Biomarker for auxiliary screening of necrotizing enterocolitis of neonate and application of biomarker | 上海市儿童医院 | 2025-05-16 | — | — | CN | claimed |
| CN-114040680-B | Methods and compositions for treating intestinal disorders | 马斯公司 | 2025-03-18 | — | — | CN | claimed |
| EP-2460014-A1 | METHOD FOR PREDICTING THE LIKELIHOOD OF AN ONSET OF AN INFLAMMATION ASSOCIATED ORGAN FAILURE | BIOCRATES Life Sciences AG (AT) | 2012-06-06 | — | — | EP | claimed |
| US-8137977-B2 | Lipidomic approaches to determining drug response phenotypes in cardiovascular disease | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) | 2012-03-20 | — | — | US | claimed |
| WO-2011161186-A1 | METHOD FOR IN VITRO DIAGNOSING SEPSIS UTILIZING BIOMARKER COMPOSED OF MORE THAN TWO DIFFERENT TYPES OF ENDOGENOUS BIOMOLECULES | BIOCRATES LIFE SCIENCES AG (AT) | 2011-12-29 | — | — | WO | claimed |
| WO-2011157655-A1 | USE OF BILE ACIDS FOR PREDICTION OF AN ONSET OF SEPSIS | BIOCRATES LIFE SCIENCES AG (AT) | 2011-12-22 | — | — | WO | claimed |
| EP-2284540-A1 | Method of diagnosing organ failure | BIOCRATES Life Sciences AG (AT) | 2011-02-16 | — | — | EP | claimed |
| WO-2011012553-A1 | METHOD FOR PREDICTING THE LIKELIHOOD OF AN ONSET OF AN INFLAMMATION ASSOCIATED ORGAN FAILURE | BIOCRATES LIFE SCIENCES AG (AT) | 2011-02-03 | — | — | WO | claimed |
| US-20090197242-A1 | Lipidomic Approaches to Determining Drug Response Phenotypes in Cardiovascular Disease | MONROE CAPITAL MANAGEMENT ADVISORS, LLC, AS ADMINISTRATIVE AGENT | 2009-08-06 | — | — | US | claimed |
| US-7137975-B2 | Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent | ACIONT, INC. (US) | 2006-11-21 | — | — | US | claimed |
| US-20020161323-A1 | Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent | ACIONT INC. | 2002-10-31 | — | — | US | claimed |
| US-4164573-A | INSULIN | GALINSKY ALVIN M | 1979-08-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569502-B2 | Use of bile acids and derivatives thereof in preparation of GPR39 agonist | GPR39, GPBAR1, GPR119 | GPBAR1 2/4885EPHA2 815/4885VDR 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.